clinical trial · NCT06258213
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
Atom Therapeutics Co., Ltd·phase1·completed·n = 90
GoutAcute Gout FlareGout FlaresABP-745Placebo
brief summary
A randomized, double-blind, placebo-controlled, dose-escalation study will be conducted in healthy volunteers. This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ABP-745 following single (Part 1) and multiple (Part 2) oral doses.
started
Jan 23, 2024
primary completion
Jul 29, 2024
completion
Jul 29, 2024
last updated
Aug 17, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol